Holen Sie sich die Stockscreener-App
3.52
5.63%
-0.21
Handel nachbörslich:
3.53
0.010
+0.28%
Schlusskurs vom Vortag:
$3.73
Offen:
$3.83
24-Stunden-Volumen:
7.41M
Relative Volume:
0.63
Marktkapitalisierung:
$691.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-6.1754
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
-32.05%
1M Leistung:
+310.30%
6M Leistung:
+112.05%
1J Leistung:
+53.04%
1-Tages-Spanne:
$3.52
$4.05
1-Wochen-Bereich:
$3.15
$5.45
52-Wochen-Spanne:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Vergleichen Sie PROK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.52 | 691.11M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Best Momentum Stocks to Buy for July 17th - TradingView
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
UBS Adjusts ProKidney Price Target to $8 From $4, Maintains Buy Rating - MarketScreener
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
Sector Update: Health Care - MarketScreener
ProKidney Soars 29.27% on FDA Milestone for CKD Therapy - AInvest
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel - MarketScreener
Prokidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - MarketScreener
ProKidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - grafa.com
ProKidney Secures FDA Alignment for Rilparencel Approval - TipRanks
Why Did ProKidney Stock Plunge 5.15% Despite 169% YTD Surge? - AInvest
ProKidney stock price target raised to $8 from $4 at UBS on promising data By Investing.com - Investing.com South Africa
ProKidney stock price target raised to $8 from $4 at UBS on promising data - Investing.com India
ProKidney stock falls after FDA alignment on rilparencel approval pathway - Investing.com
ProKidney announces alignment with FDA on rilparencel accelerated approval path - TipRanks
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewswire
ProKidney price target raised to $8 from $4 at UBS - TipRanks
ProKidney Enters New $200M Sale Agreement with Jefferies - TipRanks
ProKidney Plummets 26%—Is This the End of a Biotech Rally? - AInvest
ProKidney Faces Turbulence as Stock Plunges Amid Downgrades - StocksToTrade
ProKidney: Guggenheim maintains a 'Buy' Rating, The Target Price is $7 - AInvest
ProKidney's Innovative CKD Treatment Sparks Biotech InterestNews and Statistics - IndexBox
ProKidney stock price target raised to $7 from $6 at Guggenheim - Investing.com Australia
ProKidney stock price target raised to $7 from $6 at Guggenheim By Investing.com - Investing.com South Africa
ProKidney Just Set A New 52-Week High. Should You Buy, Sell, Or Hold PROK Stock Here? - Barchart.com
Promising clinical trial results give ProKidney share price major boost - Winston-Salem Journal
The Globe’s stars and dogs for the week - The Globe and Mail
High-Potential Biotech Penny Stocks in 2025: ProKidney and Design Therapeutics Lead the Way - AInvest
ProKidney’s Investigation: A Game Changer? - timothysykes.com
ProKidney Stock (PROK): Is the Hype Justified? - Value The Markets
ProKidney Stock Soars 11.75% on Positive Phase 2 Study Results - AInvest
Top Stocks on Investors' Radars: ProKidney, Soundhound AI, Quantumscape, Intel, and Nvidia - AInvest
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire
ProKidney spikes after mid-stage trial data for lead asset - MSN
Prokidney (PROK) chief regulatory officer Weber sells $312k in stock - Investing.com Canada
Prokidney (PROK) chief regulatory officer Weber sells $312k in stock By Investing.com - Investing.com South Africa
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):